CSA Medical Secures $53M Series D Financing for Breakthrough RejuvenAir System

CSA Medical closes an oversubscribed $53 million Series D financing round, co-led by TVM Capital Life Science and Yonjin Venture, to support the pursuit of FDA premarket approval and the U.S. launch of the RejuvenAir System.